Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ID93+GLA-SE Vaccine in Healthy Adolescents
NCT03806699Phase 1Unknown
- Sponsor
- Quratis
- Start
- Apr 2019
- Primary completion
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ID93 + GLA-SE in Tuberculosis (TB) (3 arms), sponsored by Quratis. Primary endpoint: Adverse Events at 12 months. Status: unknown.
02
Drugs
ID93 + GLA-SE
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03806699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03806699.